[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617705":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":34,"locations":40,"responsibleParty":58,"collaborators":27,"id":60,"slug":27,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":27,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":27,"studyType":72,"phases":73,"briefSummary":76,"conditions":77,"keywords":27,"overallStatus":43,"whyStopped":27,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"TORL Biotherapeutics, LLC","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Arm A: TORL-1-23 and paclitaxel","EXPERIMENTAL","Administered once every three weeks",[13],"Combination Product: TORL-1-23 and paclitaxel",{"label":15,"type":10,"description":11,"interventionNames":16},"Treatment Arm B: TORL-1-23 and carboplatin",[17],"Combination Product: TORL-1-23 and carboplatin",{"label":19,"type":10,"description":11,"interventionNames":20},"Treatment Arm C: TORL-1-23, paclitaxel, and carboplatin",[21],"Combination Product: TORL-1-23, paclitaxel, and carboplatin",[23,28,31],{"type":24,"name":25,"description":25,"armGroupLabels":26,"otherNames":27},"COMBINATION_PRODUCT","TORL-1-23 and paclitaxel",[9],null,{"type":24,"name":29,"description":29,"armGroupLabels":30,"otherNames":27},"TORL-1-23 and carboplatin",[15],{"type":24,"name":32,"description":32,"armGroupLabels":33,"otherNames":27},"TORL-1-23, paclitaxel, and carboplatin",[19],[35],{"name":36,"role":37,"phone":38,"phoneExt":27,"email":39},"Caroline Labib, PharmD","CONTACT","310-348-9636","caroline.labib@torlbio.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"UCLA","RECRUITING","Los Angeles","California","90095","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-118.24368,34.05223,{"lat":53,"lon":52},[56],{"name":57,"role":37,"phone":38,"phoneExt":27,"email":27},"Principal Investigator",{"type":59,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100617705",false,"NCT07322094","CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer","CATALINA-4: Phase 1B\u002F2 Study of TORL-1-23 With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Newly Diagnosed Patients With Advanced Stage Ovarian Cancer","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.\n* Histologically or cytologically confirmed diagnosis of epithelial ovarian, primary peritoneal or fallopian tubes cancer\n* FIGO Stage III or IV\n* Positive for claudin 6 (CLDN6) expression\n* Adequate organ function\n\nExclusion Criteria:\n\n* Clear cell, mucinous, sarcomatous, mixed histology, low-grade\u002Fborderline, or non-epithelial ovarian cancers\n* Prior systemic treatment for the disease under study\n* Prior surgery\n* Prior radiation therapy to the abdomen or pelvis\n* Current recipient or receipt within 5-half-lives of C1D1 of chemotherapy, biologic\u002Ftargeted therapy, immunomodulator therapy for any disease indication\n* Active, progressive, or symptomatic brain metastases\n* Participants considered poor medical risks due to serious, uncontrolled medical conditions, active infections, or nonmalignant systemic diseases\n* Pregnant or breastfeeding women","FEMALE","18 Years","70 Years",{"count":70,"type":71},60,"ESTIMATED","INTERVENTIONAL",[74,75],"PHASE1","PHASE2","A Phase 1B\u002F2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer",[78,79,80],"FIGO Stage III and IV Ovarian Cancer","Fallopian Tube Cancers","Primary Peritoneal Cancer","2026-01-05",{"date":83,"type":84},"2026-01-07","ACTUAL",{"date":86,"type":84},"2025-12-10",{"date":88,"type":71},"2028-01",{"name":5,"class":6},1]